Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07289763
PHASE2

Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous Nephropathy

Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd

View on ClinicalTrials.gov

Summary

To investigate the safety, efficacy, pharmacokinetics, and pharmacodynamics of SHR-2173 injection in patients with primary membranous nephropathy

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

75

Start Date

2025-12-31

Completion Date

2027-09

Last Updated

2026-01-26

Healthy Volunteers

No

Interventions

DRUG

SHR-2173 injection

SHR-2173 injection, with a total of 8 administrations

DRUG

SHR-2173 injection

SHR-2173 injection, with a total of 16 administrations

DRUG

SHR-2173 injection

SHR-2173 injection , with a total of 32 administrations

Locations (1)

General hospital of eastern theater command

Nanjing, Jiangsu, China